[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100551751":3},{"organization":4,"armGroups":7,"interventions":22,"overallOfficials":28,"centralContacts":39,"locations":48,"responsibleParty":64,"collaborators":66,"id":69,"slug":70,"hasResults":71,"nctId":72,"briefTitle":73,"officialTitle":74,"acronym":75,"eligibilityCriteria":76,"healthyVolunteers":71,"sex":77,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":10,"studyType":83,"phases":10,"briefSummary":84,"conditions":85,"keywords":86,"overallStatus":51,"whyStopped":10,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Assistance Publique - Hôpitaux de Paris","OTHER",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"Preeclampsia",null,"Pregnancy with preeclampsia",[13],"Biological: Biological collection",{"label":15,"type":10,"description":16,"interventionNames":17},"Pregnancies with intra uterine growth restriction (IUGR)","Pregnancy with intra uterine growth restriction (IUGR)",[13],{"label":19,"type":10,"description":20,"interventionNames":21},"Normal pregnancy","Pregnancy without preeclampsia and intra uterine growth restriction (IUGR) and complications",[13],[23],{"type":24,"name":25,"description":26,"armGroupLabels":27,"otherNames":10},"BIOLOGICAL","Biological collection","A collection of maternal plasma, serum and urine",[19,9,15],[29,32,36],{"name":30,"affiliation":5,"role":31},"Vassilis TSASARIS, MD, PhD","PRINCIPAL_INVESTIGATOR",{"name":33,"affiliation":34,"role":35},"Edouard LECARPENTIER, MD, PhD","Institut National de la Santé Et de la Recherche Médicale, France","STUDY_CHAIR",{"name":37,"affiliation":5,"role":38},"Jean GUIBOURDENCHE, MD, PhD","STUDY_DIRECTOR",[40,44],{"name":30,"role":41,"phone":42,"phoneExt":10,"email":43},"CONTACT","+33 158413871","vassilis.tsasaris@aphp.fr",{"name":45,"role":41,"phone":46,"phoneExt":10,"email":47},"Charly LARRIEU","+33 1 58 41 34 78","charly.larrieu@aphp.fr",[49],{"facility":50,"status":51,"city":52,"state":10,"zip":53,"country":54,"countryCode":55,"cosmosGeoPoint":56,"geoPoint":61,"contacts":62},"Maternité Port-Royal","RECRUITING","Paris","75014","France","FR",{"type":57,"coordinates":58},"Point",[59,60],2.3488,48.85341,{"lat":60,"lon":59},[63],{"name":30,"role":31,"phone":10,"phoneExt":10,"email":10},{"type":65,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[67],{"name":68,"class":6},"URC-CIC Paris Descartes Necker Cochin","100551751","new-therapeutic-strategy-against-preeclampsia-100551751",false,"NCT06464159","New Therapeutic Strategy Against Preeclampsia","New Therapeutic Strategy Against Preeclampsia : Angiogenic Switch to Physiological State by Extracorporeal Removal of sFlt-1 and Release of PlGF","APHERESE2","Inclusion Criteria:\n\n* Age from 18 to 50 years old\n* Singleton pregnancies between 20 and 41 weeks of gestation\n* Preeclampsia \u002F normal pregnancy\n\nExclusion Criteria:\n\n* Age \\\u003C 18 years old\n* Infectious disease: HIV, HBV or HCV\n* Multiple pregnancies\n* refusal to participate in the protocol\n* Lack of social security cover","FEMALE","18 Years","50 Years",{"count":81,"type":82},100,"ESTIMATED","OBSERVATIONAL","Preeclampsia is a hypertensive disorder of pregnancy associated with important maternal and perinatal mortality. It complicates 2 to 5% of pregnancies and causes more than 70 000 maternal deaths each year worldwide. Although symptomatic management has improved there is currently no curative treatment, and only childbirth and delivery of the placenta, usually prematurely, alleviate the mother's symptoms. The management of extremely preterm infants is a major societal challenge in medical, ethical and economic terms.\n\nPlacental insufficiency plays a central role in the pathophysiology of preeclampsia. Abnormal placentation during the first trimester leads to placental hypoperfusion, which induces trophoblast dysfunction and the release in maternal circulation of trophoblastic factors leading to the maternal symptoms. Among molecules that participate to the pathophysiology of preeclampsia, one of the most important players is soluble fms-like tyrosine kinase 1 (sFlt-1), which is a soluble form of the vascular endothelial growth factor (VEGF) and placenta growth factor (PlGF) receptor. sFlt-1 binds to free VEGF and PlGF in the maternal circulation, thus reducing their bioavailability for their membrane receptors. Targeting the sFlt-1 pathway is one of the most promising strategies for the development of new treatments for preeclampsia. As sFlt-1 results from alternative splicing, its peptide sequence is identical to that of the extracellular part of the membrane receptor. The development of drugs that act specifically on the soluble form and not on the membrane form is therefore particularly complex.\n\nThe general objective of this research is to restore the angiogenic balance that maintains the physiological concentrations of free angiogenic factors in order to significantly prolong the pregnancy and diminish the consequences of the great prematurity. The precise objectives of the APHERESE 2 project are:\n\n1. To transpose the proof of concept of the APHERESE1 project to the scale of a real apheresis column\n2. To develop an innovative assay technology to determine the global circulating angiogenic balance for each patient",[9],[9,87,88,89,90,91,92,93],"Apheresis","Angiogenic factors","Maternal biomarkers","sFLt-1","PIGF","Placenta","Pregnancy","2026-04-30",{"date":96,"type":97},"2026-05-06","ACTUAL",{"date":99,"type":97},"2026-02-10",{"date":101,"type":82},"2028-11",{"name":5,"class":6},1]